Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29890980 | 0.90 | ACHE (0.64) | ACHEKDM4EPKMGPR119BRD4 | |
| SCHEMBL8825578 | 0.90 | ACHE (0.64) | ACHEKDM4EPKMGPR119BRD4 | |
| SCHEMBL6953531 | 0.89 | ACHE (0.55) | ACHEKDM4EPKMGPR119 | |
| SCHEMBL21458995 | 0.87 | PRMT5 (0.46) | KDM4EPKMGPR119BRD4L3MBTL1 | |
| SCHEMBL30869860 | 0.87 | PRMT5 (0.46) | KDM4EPKMGPR119BRD4L3MBTL1 | |
| SCHEMBL30869882 | 0.87 | PRMT5 (0.46) | KDM4EPKMGPR119BRD4L3MBTL1 | |
| SCHEMBL5475624 | 0.87 | ACHE (0.53) | ACHEKDM4EPKMGPR119 | |
| SCHEMBL7516299 | 0.86 | KDM4E (0.49) | ACHEKDM4EPKMGPR119BRD4 | |
| SCHEMBL31596884 | 0.86 | GPR119 (0.53) | ACHEKDM4EPKMGPR119 | |
| SCHEMBL22123837 | 0.85 | ALDH1A1 (0.49) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | UPPTHERA INC. (KR) | 2025-11-25 | — | — | US | disclosed |
| US-20230078961-A1 | HMG-CoA Reductase Degradation Inducing Compound | UPPTHERA INC. (KR) | 2023-03-16 | — | — | US | disclosed |
| WO-2021201577-A1 | HMG-COA REDUCTASE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230078961-A1 | HMG-CoA Reductase Degradation Inducing Compound | HMGCR, HMGB2, LDLR | ACHE 4140/4885KDM4E 745/4885PKM 1875/4885 |
| US-12479840-B2 | HMG-CoA reductase degradation inducing compound | HMGCR, HMGB2, LDLR | ACHE 4140/4885KDM4E 745/4885PKM 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.